Recognized for application of AI-based medical technology in early cancer detection.
Helio Genomics, an AI-driven healthcare company specializing in diagnostics technology and test development for cancer detection, has been honored by the California Investment Forum (CIF) for its innovations in utilizing AI-based technology in developing its HelioLiver test for early liver cancer detection.
CIF fosters international investment and economic development by connecting investors with groundbreaking projects in clean energy, biotechnology, artificial intelligence and real estate development. Its extensive network includes partnerships with top academic institutions as well as collaborations with government agencies and major venture capital firms.
The 2024 Innovation Awards program recognized groundbreaking companies that are leading the charge toward a sustainable, prosperous and innovative future. It offers a unique opportunity for ambitious companies to showcase their contributions to industry and society, connecting with global leaders and sparking meaningful collaborations. The program is sponsored by California State Treasurer Fiona Ma and California State Controller Malia Cohen.
Helio was presented with the award for AI-Based Medical Technology as applied to its HelioLiver breakthrough. HelioLiver is a multi-analyte blood test that analyzes cell-free DNA (cfDNA), methylation patterns, serum protein markers and demographic information with a simple blood draw to detect hepatocellular carcinoma, or HCC, the most common form of liver cancer.
Criteria for the award included:
Innovation: Helio Genomics has developed advanced early cancer detection technology using AI, particularly their HelioLiver test, which significantly enhances early liver cancer detection.
Impact: Their technology has the potential to greatly improve diagnostic accuracy and patient outcomes, thereby saving more lives.
Practicality and Scalability: The blood test method they use is simple, easy to implement, and scalable across various medical settings.
Market Performance: Helio Genomics has shown excellent market performance, securing multiple funding rounds and receiving industry recognition, proving their business model’s sustainability.
Academic and Clinical Validation: Their technology has undergone rigorous clinical trials and research validation, ensuring its safety and effectiveness.
Industry Recognition: Helio Genomics has received several industry awards and recognitions, further proving their leadership in medical technology.
Helio’s mission is to transform the paradigm of cancer screening by developing multi-analyte blood tests with greater sensitivity, specificity and ease-of-use compared to current screening modalities using AI technology.
For information on Helio Genomics and its innovative solutions for early cancer detection, visit www.heliogenomics.com.